A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from Baylor College of Medicine, ...
The MarketWatch News Department was not involved in the creation of this content. Repertoire and Pioneering Medicines, Flagship's in-house drug development unit, will jointly conduct research ...
Researchers combined advanced imaging techniques with a computational method to probe how immune cells interact with each other, revealing that the interactions between immune cells in the vicinity of ...
Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases. One key component of these pathways is Lymphocyte Activation Gene 3 ...
Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune ...
Please provide your email address to receive an email when new articles are posted on . Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease ...
A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from Baylor College of Medicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results